ZA200809493B - Method of treatment of age-related macular degeneration (AMD) - Google Patents

Method of treatment of age-related macular degeneration (AMD)

Info

Publication number
ZA200809493B
ZA200809493B ZA200809493A ZA200809493A ZA200809493B ZA 200809493 B ZA200809493 B ZA 200809493B ZA 200809493 A ZA200809493 A ZA 200809493A ZA 200809493 A ZA200809493 A ZA 200809493A ZA 200809493 B ZA200809493 B ZA 200809493B
Authority
ZA
South Africa
Prior art keywords
amd
age
treatment
macular degeneration
related macular
Prior art date
Application number
ZA200809493A
Other languages
English (en)
Inventor
Ashley Bush
Colin Louis Masters
Penelope Jane Huggins
Jack Gordon Parsons
Gaik Beng Kok
Vijaya Kenche
Sous Mariana El
Original Assignee
Prana Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prana Biotechnology Ltd filed Critical Prana Biotechnology Ltd
Publication of ZA200809493B publication Critical patent/ZA200809493B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200809493A 2006-04-14 2007-04-13 Method of treatment of age-related macular degeneration (AMD) ZA200809493B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79227806P 2006-04-14 2006-04-14

Publications (1)

Publication Number Publication Date
ZA200809493B true ZA200809493B (en) 2010-08-25

Family

ID=38608967

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA200809493A ZA200809493B (en) 2006-04-14 2007-04-13 Method of treatment of age-related macular degeneration (AMD)
ZA2010/05922A ZA201005922B (en) 2006-04-14 2010-08-19 Method of treatment of age-related macular degeneration (amd)

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA2010/05922A ZA201005922B (en) 2006-04-14 2010-08-19 Method of treatment of age-related macular degeneration (amd)

Country Status (14)

Country Link
US (3) US20100144693A1 (https=)
EP (2) EP2012789B1 (https=)
JP (1) JP5290147B2 (https=)
KR (2) KR20080109096A (https=)
CN (3) CN101987849B (https=)
AU (2) AU2007240120A1 (https=)
BR (2) BRPI0722382A2 (https=)
CA (1) CA2683756A1 (https=)
DK (1) DK2012789T3 (https=)
ES (1) ES2437997T3 (https=)
IL (1) IL207495A (https=)
NZ (2) NZ572591A (https=)
WO (1) WO2007118276A1 (https=)
ZA (2) ZA200809493B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
PT1888548E (pt) 2005-05-26 2012-10-30 Neuron Systems Inc Derivado de quinolina para o tratamento de doenças da retina
CA2656825C (en) 2006-06-22 2013-12-10 Prana Biotechnology Limited Method of treatment and agents useful for same
US9284297B2 (en) * 2008-08-11 2016-03-15 President And Fellows Of Harvard College Halofuginone analogs for inhibition of tRNA synthetases and uses thereof
US8889695B2 (en) 2008-12-24 2014-11-18 Prana Biotechnology Limited Quinazolinone compounds
MA33090B1 (fr) 2009-01-26 2012-03-01 Michael Spino Utilisation de deferiprone pour le traitement et la prevention de troubles oculaires lies au fer
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
WO2012122534A2 (en) 2011-03-10 2012-09-13 The Trustees Of Columbia University In The City Of New York N-quinolin-benzensulfonamides and related compounds for the treatment of cancer, autoimmune disorders and inflammation
AU2013207796B2 (en) 2012-01-13 2017-04-27 President And Fellows Of Harvard College Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
RU2015120478A (ru) * 2012-12-20 2017-01-25 Альдейра Терапьютикс, Инк. Пери-карбинолы
CA2898631C (en) 2013-01-23 2023-06-13 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
SG11201505599YA (en) 2013-01-25 2015-08-28 Aldeyra Therapeutics Inc Novel traps in the treatment of macular degeneration
WO2016086261A1 (en) * 2014-12-02 2016-06-09 Prana Biotechnology Limited 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS
CN107533181B (zh) * 2015-04-29 2020-06-30 特里亚佩克斯有限公司 偏光膜、制备它的方法及包含它的偏光镜片
US10781178B2 (en) * 2015-08-12 2020-09-22 The General Hospital Corporation 8-hydroxyquinoline derivatives as diagnostic and therapeutic agents
CN118724806A (zh) 2015-08-21 2024-10-01 奥尔德拉医疗公司 氘化化合物和其用途
WO2017053696A2 (en) * 2015-09-24 2017-03-30 University Of Florida Research Foundation, Incorporated Halogenated quinoline derivatives as antimicrobial agents
US11129823B2 (en) 2016-05-09 2021-09-28 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
EP3478288A4 (en) 2016-07-01 2020-03-04 Prana Biotechnology Ltd METHOD OF TREATING IMMUNOGLOBULIN LIGHT-CHAIN AMYLOSIS
MX2019010576A (es) 2017-03-16 2019-10-07 Aldeyra Therapeutics Inc Compuestos polimorficos y usos de los mismos.
JP7311162B2 (ja) 2017-10-10 2023-07-19 アルデイラ セラピューティクス， インコーポレイテッド 炎症性障害の処置
WO2019237125A1 (en) 2018-06-08 2019-12-12 The General Hospital Corporation Inhibitors of prolyl-trna-synthetase
WO2020033344A1 (en) 2018-08-06 2020-02-13 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
CN109232396B (zh) * 2018-11-27 2020-07-03 聊城大学 酰胺吡啶类衍生物及其用途
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CN113784954A (zh) 2019-05-02 2021-12-10 奥尔德拉医疗公司 多晶型化合物和其用途
CA3175856A1 (en) 2020-05-13 2021-11-18 Todd Brady Pharmaceutical formulations and uses thereof
WO2022006439A2 (en) * 2020-07-02 2022-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compound embodiments for treating retinal degeneration and method embodiments of making and using the same
US12060334B2 (en) 2021-03-12 2024-08-13 University Of Florida Research Foundation, Incorporated 3-substituted phenazine derivatives as antimicrobial agents
CN113214249B (zh) * 2021-04-23 2023-09-19 成都大学 吡啶并[1,2-a]嘧啶-4-硫酮化合物的合成方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE505711A (https=) 1950-09-09
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
HU178910B (en) * 1977-08-19 1982-07-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing 2,3-disubstituted-4-oxo-4h-pyrido/1,2-a/-pyrimidines
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
IT1204612B (it) 1987-05-14 1989-03-10 Bioresearch Spa Pteridine atte alla preparazione di composizioni farmaceutiche ad attivita' antiamnesica
US5314909A (en) * 1993-03-17 1994-05-24 Merck & Co., Inc. Use of non-steroidal antiiflammatory agents in macular degeneration
WO1994024379A1 (de) 1993-04-08 1994-10-27 Ideal-Standard Gmbh Sanitäres wasserventil
US5631373A (en) 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
DE4418096A1 (de) * 1994-05-24 1995-11-30 Cassella Ag Verwendung von Pteridin-Derivaten als Hemmstoffe der NO-Synthase
US6168776B1 (en) 1994-07-19 2001-01-02 University Of Pittsburgh Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US5801183A (en) 1995-01-27 1998-09-01 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists
AU720643B2 (en) 1996-08-13 2000-06-08 P.N. Gerolymatos S.A. Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of Alzheimer's disease
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
US5939421A (en) 1997-07-01 1999-08-17 Signal Pharmaceuticals, Inc. Quinazoline analogs and related compounds and methods for treating inflammatory conditions
US20020025944A1 (en) * 2000-04-28 2002-02-28 Bush Ashley I. Use of clioquinol for the therapy of Alzheimer's disease
US6337332B1 (en) * 1998-09-17 2002-01-08 Pfizer Inc. Neuropeptide Y receptor antagonists
OA11665A (en) 1998-10-22 2004-12-08 Neurosearch As Substituted phenyl derivatives, their preparation and use.
US6369058B1 (en) * 1999-02-04 2002-04-09 New Millennium Pharmaceutical Research Inc. Brain delivery of folic acid for the prevention of alzheimer's disease and stroke
JP4831906B2 (ja) 1999-08-27 2011-12-07 ケモセントリックス， インコーポレイテッド Ｃｘｃｒ３機能を調節するための複素環式化合物および方法
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
NZ526472A (en) 2000-12-21 2004-04-30 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
FR2819187A1 (fr) * 2001-01-10 2002-07-12 Michel Xilinas Utilisation des substances chelatrices pour le traitement et la prevention de la deferrescence oculaire
EP1389209B1 (en) 2001-04-24 2009-04-08 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
FR2827599A1 (fr) * 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
US20050014780A1 (en) 2001-08-17 2005-01-20 Maligres Peter E. Process for preparing 5-sulfonamido-8-hydroxy-1,6-naphthyridine-7-carboxamides
AU2003211560A1 (en) 2002-02-20 2003-09-09 Ajinomoto Co., Inc. Novel phenylalanine derivative
ES2361403T3 (es) 2002-03-07 2011-06-16 X-Ceptor Therapeutics, Inc. Moduladores de quinazolinona de receptores nucleares.
AU2002950217A0 (en) * 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
AU2002951868A0 (en) * 2002-10-04 2002-10-24 Prana Biotechnology Limited Compound i
MXPA05003607A (es) * 2002-10-04 2005-11-17 Prana Biotechnology Ltd Compuestos neurologicamente activos.
WO2004087160A1 (en) * 2003-04-03 2004-10-14 Prana Biotechnology Ltd Treatment of neurological conditions
JP5146714B2 (ja) * 2003-06-23 2013-02-20 ビーエイチアイ リミテッド パートナーシップ アミロイド関連疾患を治療するための方法および組成物
NZ551004A (en) * 2004-04-02 2010-07-30 Prana Biotechnology Ltd Neurologically-active compounds
WO2006083533A2 (en) * 2005-01-14 2006-08-10 The Regents Of The University Of California Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
WO2006117660A2 (en) * 2005-05-04 2006-11-09 Clio Pharmaceutical Corporation Method for treating cancer, coronary, inflammatory and macular disease, combining the modulation of zinc- and/or copper dependent proteins
CA2656825C (en) * 2006-06-22 2013-12-10 Prana Biotechnology Limited Method of treatment and agents useful for same

Also Published As

Publication number Publication date
CN101987849B (zh) 2013-05-08
CN101987849A (zh) 2011-03-23
US20110071167A1 (en) 2011-03-24
KR20100110396A (ko) 2010-10-12
KR20080109096A (ko) 2008-12-16
WO2007118276A1 (en) 2007-10-25
US9163018B2 (en) 2015-10-20
US20140088122A1 (en) 2014-03-27
AU2010206074A1 (en) 2010-08-19
ES2437997T3 (es) 2014-01-15
NZ572591A (en) 2012-01-12
AU2007240120A2 (en) 2008-12-18
AU2007240120A1 (en) 2007-10-25
EP2012789B1 (en) 2013-09-25
US20100144693A1 (en) 2010-06-10
NZ590271A (en) 2011-12-22
EP2514423A3 (en) 2012-12-19
EP2012789A1 (en) 2009-01-14
JP2009533356A (ja) 2009-09-17
DK2012789T3 (da) 2013-12-16
EP2514423A2 (en) 2012-10-24
EP2012789A4 (en) 2011-02-16
JP5290147B2 (ja) 2013-09-18
IL207495A (en) 2015-05-31
ZA201005922B (en) 2013-09-25
IL207495A0 (en) 2010-12-30
BRPI0722382A2 (pt) 2012-06-05
CN102225930A (zh) 2011-10-26
BRPI0710737A2 (pt) 2011-05-10
AU2010206074B2 (en) 2012-08-30
CA2683756A1 (en) 2007-10-25
CN101534826A (zh) 2009-09-16

Similar Documents

Publication Publication Date Title
ZA201005922B (en) Method of treatment of age-related macular degeneration (amd)
EP2032131A4 (en) Methods of Treatment
PL2187880T3 (pl) Kompozycje i sposoby do leczenia zwyrodnienia plamki żółtej
PL2252317T3 (pl) Leczenie zwyrodnienia plamki żółtej
EP2194780A4 (en) METHOD FOR TREATING GLAUCOMA BY RASAGILINE
DK2044223T3 (da) Diagnosticering og behandling af aldersrelateret makuladegeneration
ZA201008201B (en) Novel compositions and methods for treating hyperproliferative diseases
WO2007098122A3 (en) Methods for the treatment of macular degeneration and related eye conditions
PL2061501T3 (pl) Sposób leczenia zaburzeń oddechowych
GB0510196D0 (en) Composition for treatment of a detached retina and method of production thereof
EP2083841A4 (en) TREATMENT OF MACULAR DEGENERATION FROM AGING AND OTHER OCULAR DISEASES
PL2508182T3 (pl) Hydralazyna do stosowania w leczeniu związanego z wiekiem zwyrodnienia plamki
GB0610746D0 (en) Method of treatment
GB2445651B (en) Well treatment products and methods of using them
IL173971A0 (en) Compositions and methods for treating and preventing age-related macular degeneration
EP2194793A4 (en) PROCESS FOR TREATING FRESH FRUITS AND VEGETABLES
ZA200707420B (en) Methods and reagents for treatment and diagnosis of age-related macular degeneration
IL213550A0 (en) Method for treating macular degeneration
GB0625844D0 (en) The treatment of macular degeneration
GB0713367D0 (en) Apparatus amd method of treating filter elements
GB0501129D0 (en) Method of treatment by administration of RNA
EP2203432A4 (en) PROCESSING METHOD
IL197486A0 (en) Novel method of treatment of male sub-fertility
HK1127858A (en) Copolymer-1 for treatment of age-related macular degeneration
IL196173A0 (en) Use of agents that act on t cells for treatment of age-related macular degeneration